Skip to Content

Lung/Thoracic Cancer Trials

The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments, and complications that people with thoracic tumors may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Kanwal Zeeshan at 847.570.1697
Open to Enrollment: Yes

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-
Small Cell Lung Cancer

Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH19-106
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

E4512: Testing the Addition of Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition, crizotinib may help prevent your cancer from returning, but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to determine if patients with Non-Small Cell Lung Cancer (NSCLC) have a mutation (abnormal change) in the DNA or their tumor and if so, which one.  The genetic mutations which are being assessed are EGFR, ALK, and dPD-L1.  Not all lung tumors have changes in genes.  The study will lead into two optional treatment trials that will use specific drugs to target these genes as well as tumors without mutations.  Tissue from the tumor removed at the time of surgery is sent to a national laboratory to be analyzed and compared to local results. 
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stage IB, II, IIIA
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes

A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)
Aims: The purpose is to see if adding the drug pembrolizumab to standard therapy will lower the change of lung cancer coming back.
Principal Investigator: Thomas Hensing, MD 
IRB Approval Number: EH20-364
Sponsor: Alliance
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes

Best Practice in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study that will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo-Surgery
Contact: Interested participants may contact Kanwal Zeesha, MBBS, CCRP at 847.570.1697, kzeesha@northshore.org
Open to Enrollment
: Yes 

NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Aims:
The purpose of this research study is to see if the addition of atezolizumab  can lower the chance of small cell lung cancer from growing or spreading.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH20-114
Sponsor: NRG Oncology
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes

EA5163: A Randomized Phase III Study of Firstline Immunotherapy alone on in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
Aims: The purpose of this research study is to see if starting treatment with immunotherapy instead of chemotherapy and immunotherapy together is better.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH19-224
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

Mirati 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Aims: The purpose of this research study is to compare the treatment with immunotherapy and an investigational drug, sitravatinib, to chemotherapy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH19-224
Sponsor: Mirati Therapeutics
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment:
Yes

EA5181: A Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Aims: The purpose is to see if addinb the drug, durvalumab, during chemotherapy/radiation will prevent the tumor from coming back.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH20-371
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment:
Yes

AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-MET+ Non-Small Call Lung Cancer
Aims: The purpose of this research study is to see the good/bad effects of Vedotin and see if it prevents the lung cancer from getting worse.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH20-055
Sponsor: AbbVie, Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment:
Yes